Insulet (STU:GOV) Payments of Debt: €-889 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:GOV Insulet Corp STU:GOV
77 GF Score
Price €143.40
GF Value €348.98
Valuation Significantly Undervalued
View Full Analysis

What is Insulet Payments of Debt?

Insulet STU:GOV -0.10% 77 Payments of Debt is €-889 Mil as of Mar. 2026. GuruFocus rates STU:GOV with a GF Score™ of 77/100 and a GF Value™ of €348.98 (Significantly Undervalued).

Insulet's Payments of Debt for the three months ended in Mar. 2026 was €-4 Mil.

Insulet's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was €-889 Mil.

Insulet Payments of Debt Related Terms

Insulet Payments of Debt Historical Data

* Premium members only.

The historical data trend for Insulet's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insulet Payments of Debt Chart

Insulet Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -427.63 -37.57 -24.76 -206.38 -1,036.93

Insulet Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -168.91 -362.23 -453.26 -69.86 -3.89
STU:GOV
77GF Score
Insulet Corp STU:GOV
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insulet Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-889 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of €-889 Mil mean?
Insulet (STU:GOV) has a Payments of Debt of €-889 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Insulet and its competitors.
Is Insulet's Payments of Debt too high?
Insulet's current Payments of Debt is €-889 Mil. Overall, Insulet has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Insulet's Payments of Debt compare to GMED and PEN?
Insulet's Payments of Debt of €-889 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Medical Devices & Instruments company?
A good Payments of Debt depends on the Medical Devices & Instruments industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Insulet and its competitors. Insulet's current Payments of Debt is €-889 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insulet stock overvalued right now?
Based on GuruFocus' analysis, Insulet (STU:GOV) is currently considered Significantly Undervalued. The stock's GF Value™ is €348.98, compared to a current price of €143.40 — trading 58.9% below its estimated fair value. The current Payments of Debt is €-889 Mil. Insulet's overall GF Score™ is 77/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Insulet (STU:GOV), the current Payments of Debt is €-889 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insulet (STU:GOV) Overvalued in 2026?

Based on GuruFocus' analysis, Insulet stock appears to be undervalued. The current stock price of €143.40 is trading 58.9% below its estimated GF Value™ of €348.98. GuruFocus considers Insulet to be Significantly Undervalued.

Key valuation signals for STU:GOV:

  • Payments of Debt: €-889 Mil
  • GF Value™: €348.98 vs. price of €143.40 (58.9% below fair value)
  • GF Score™: 77/100

No single metric tells the full story. See the STU:GOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insulet Business Description

Address 100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
77GF Score

Get the complete analysis for STU:GOV

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€143.40
Price
€348.98
GF Value